Rumors are saying that French Cellectis is in talks about its potential sale. US-giant Pfizer is considered to be among the buyers.
According to The Financial Time, two people familiar with the situation said Cellectis was in negotiations over a deal, but warned no outcome was certain. The Financial Time also declared that “one person said Pfizer has approached the company about a deal that could value it at as much as €1.5 billion”. No information are suggesting that other parties are also in the sale talks with Cellectis.
Pfizer and Cellectis declined to comment this rumor but of course, the market reacts immediately with a 14% increase of Cellectis’ shares.
Cellectis intends to reprogrammed T-cells to make your own body immunized against cancer cells. To do so,